Contents
Contributors
Search

TABLE OF CONTENTS

  • INTRODUCTION
  • Characteristics of the Aging Process Relevant to Lipid Intervention
  • Physiologic characteristics of aging:
  • Socio-economic characteristics of aging:
  • Ethical considerations in the very old:
  • LIPOPROTEINS & AGING
  • Biochemistry and Metabolism of Lipoproteins
  • Chylomicron metabolism:
  • VLDL metabolism:
  • LDL metabolism:
  • HDL metabolism:
  • Lipoprotein (a):
  • Changes of Lipoproteins with Aging
  • LIPIDS, CARDIOVASCULAR RISK AND AGING
  • Total Cholesterol, LDL Cholesterol and Non-HDL Cholesterol as Risk Factors
  • Other Lipids and Lipoproteins as Risk Factors
  • Inflammatory Markers as Risk Factors
  • LIPID INTERVENTION FOR CARDIOVASCULAR PREVENTION
  • Lifestyle Changes and Lipoproteins
  • Lipid Lowering Drugs and Cardiovascular Risk
  • Statins
  • PPAR activators
  • Bile Acid Binding Resins
  • Niacin
  • Cholesterol absorption inhibitors
  • Omega-3 fatty acids
  • Combination therapy
  • LIPID LOWERING DRUGS AND CARDIOVASCULAR PREVENTION
  • Statin Cardiovascular Clinical Trials
  • Frailty, the unexplored territory
  • Pathohysiology, epidemiology ans clinical aspects
  • Statins in patients with ESRD and CHF
  • Cholesterol lowering in patients with vascular calcification
  • STATIN CLINICAL TRIALS WITH OUTCOMES OTHER THAN CARDIOVASCULAR ACUTE EVENTS
  • Peripheral Arterial Disease
  • Preoperative use
  • Renal endpoints
  • Anti-inflammatory effects
  • Anti-arrhythmic effects
  • Prevention and treatment of Alzheimer’s disease.
  • CARDIOASCULAR TRIALS WITH OTHER LIPID LOWERING DRUGS
  • Fibrates
  • Niacin
  • Lovaza
  • Probucol
  • TREATMENT OF HYPERLIPIDEMIA-INDUCED PANCREATITIS
  • Diet
  • Insulin and Heparin
  • Plasmpheresis
  • Fibric Acid Derivatives
  • Niacin
  • Fish Oil
  • Anti-oxidants
  • Acipimox
  • SAFETY OF LIPID LOWERING DRUGS IN THE ELDERLY
  • Pathophysiology of Drug Interaction and Toxicity
  • Muscle toxicity of lipid lowering drugs
  • Myalgia
  • Elevation of CK levels without symptoms
  • Myopathy
  • Rhabdomyolysis
  • Hepatotoxicity of lipid lowering drugs
  • Other toxicity of lipid lowering drugs
  • Renal toxicity
  • Central and peripheral nervous system
  • Cancer and lipid lowering drugs
  • Risk attributable to drug interaction
  • EPIDEMIOLOGY OF PRESCRIBING LIPID LOWERING DRUGS FOR THE ELDERLY
  • SHOULD LIPID LOWERING DRUGS BE PRESCRIBED FOR THE ELDERLY?
  • EPIDEMIOLOGY OF PRESCRIBING LIPID LOWERING DRUGS FOR THE ELDERLY
  • SHOULD LIPID LOWERING DRUGS BE PRESCRIBED FOR THE ELDERLY?